News Sentiment

DFTX sentiment intelligence

Definium Therapeutics, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 47.07 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+6.5% over one week, +90.2% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction 6.5% Price confirming higher
Trend fit Trend active 90.2% over four weeks
Fair value 377.5% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 33
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 10
TradingView 8
Investing.com 6
marketscreener.com 5
simplywall.st 4
Sahm 2
Morningstar 1

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 17
Analyst action 7
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 62
TradingView Direct company coverage

ETFs Investing in Definium Therapeutics, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Definium Therapeutics, Inc. It provides a detailed table with each ETF's market value, weight of Definium stock, issuer, management style, focus, expense ratio, assets under management (AUM), current pric

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 00:40
Source
TradingView
Stock Titan Direct company coverage

Definium (DFTX) CEO sells 29,208 shares to cover RSU tax obligations

Definium Therapeutics, Inc. CEO Robert Barrow sold 29,208 common shares at $45.03 each on June 25, 2026. This transaction was conducted to satisfy withholding tax obligations related to vested restricted stock units under a pre-arranged Rule 10b5-1 sell-to-cover plan. Following t

Tone
Negative 39/100
Event
Market update
Published
26 Jun 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] Definium Therapeutics, Inc. Insider Trading Activity

Definium Therapeutics CFO Brandi Roberts disposed of 3,013 common shares at $45.03 each on June 25, 2026. This transaction was a "sell-to-cover" event to satisfy tax obligations from vested restricted stock units, executed under a pre-arranged Rule 10b5-1 trading plan. Following

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 20:30
Source
Stock Titan
Simply Wall Street Direct company coverage

Definium Therapeutics (DFTX) Lands Phase 3 Win And Raises $700 Million For DT120

Definium Therapeutics (NasdaqGS:DFTX) announced positive topline Phase 3 results for DT120, its major depressive disorder treatment, and simultaneously completed a US$700 million equity offering. This funding is intended to support the regulatory and commercialization efforts for

Tone
Positive 71/100
Event
Earnings
Published
26 Jun 2026 13:40
Source
Simply Wall Street
Stock Titan Direct company coverage

Definium closes $805M upsized stock offering | DFTX Stock News

Definium Therapeutics, Inc. announced the closing of its upsized underwritten public offering, raising $805 million. The offering included the full exercise of the underwriters’ option to purchase additional shares, with all 23,676,471 common shares sold at $34.00 each. Definium

Tone
Positive 69/100
Event
Market update
Published
26 Jun 2026 09:41
Source
Stock Titan
BioSpace Direct company coverage

Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Definium Therapeutics, Inc. has announced the closing of an upsized public offering, raising $805 million. This includes the full exercise of the underwriters’ option to purchase additional shares. The funds will be used for research and development of product candidates, prepara

Tone
Positive 71/100
Event
Market update
Published
26 Jun 2026 04:11
Source
BioSpace